InspireMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 06, 2023 at 07:00 am EST
Share
InspireMD, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 1.56 million compared to USD 1.43 million a year ago. Net loss was USD 5.18 million compared to USD 4.53 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.58 a year ago.
For the nine months, sales was USD 4.44 million compared to USD 4.15 million a year ago. Net loss was USD 14.51 million compared to USD 13.65 million a year ago. Basic loss per share from continuing operations was USD 0.69 compared to USD 1.75 a year ago.
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.